← The Wire
GILDNasdaq
GILEAD SCIENCES, INC.
Biological Products, (No Diagnostic Substances) · DE · CIK 882095
Gilead Sciences discovers, develops, and delivers innovative medicines to prevent and treat life-threatening diseases like HIV, viral hepatitis, COVID-19, and cancer
🔥 High media attention
$155.93B
Market cap
$126.33
Last close
-1.2%
1D
+1.2%
5D
6.9M
Volume
Price · last 39 sessions-4.8%
May 4L $121.48 · H $136.30Jun 29
172
Total filings
May 20, 2026
Last filing
12/31
Fiscal year end
8-KMaterial Agreement · New Debt / ObligationMay 20, 2026424B5424B5May 18, 2026424B5424B5May 14, 202610-QFORM 10-QMay 7, 20268-KResults of OperationsMay 7, 20268-KShareholder VoteMay 4, 20268-KReg FD Disclosure · Company UpdateApr 28, 2026SC 13D/ASC 13D/AApr 28, 2026DEFA14ADEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALSMar 20, 2026DEF 14ADEFINITIVE PROXY STATEMENTMar 20, 202610-KFORM 10-KFeb 24, 20268-KMaterial Agreement · Reg FD DisclosureFeb 23, 2026SC 13DSC 13DFeb 23, 20268-KResults of OperationsFeb 10, 20268-KExecutive ChangeNov 19, 202510-QFORM 10-QNov 7, 20258-KResults of OperationsOct 30, 20258-KReg FD DisclosureOct 6, 20258-KExecutive ChangeAug 14, 202510-QFORM 10-QAug 7, 20258-KResults of OperationsAug 7, 20258-KBylaw AmendmentAug 4, 20258-KShareholder VoteMay 8, 202510-QFORM 10-QMay 7, 20258-KResults of OperationsApr 24, 2025DEFA14ADEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALSMar 27, 2025DEF 14ADEFINITIVE PROXY STATEMENTMar 27, 20258-KExecutive ChangeMar 12, 202510-KFORM 10-KFeb 28, 20258-KResults of OperationsFeb 11, 20258-K/AExecutive ChangeDec 13, 20248-KMaterial Agreement · New Debt / ObligationNov 20, 2024424B5424B5Nov 15, 2024424B5424B5Nov 13, 202410-QFORM 10-QNov 12, 20248-KResults of OperationsNov 6, 202410-QFORM 10-QAug 8, 20248-KResults of OperationsAug 8, 20248-KExecutive ChangeJul 17, 20248-KBylaw Amendment · Shareholder VoteMay 9, 202410-QFORM 10-QMay 8, 20248-KResults of OperationsApr 25, 2024SC 13GSC 13GApr 19, 2024SC 13GSC 13GApr 5, 2024DEFA14AGILEAD SCIENCES, INC. - DEFA14AMar 28, 2024DEF 14AGILEAD SCIENCES, INC. - DEF 14AMar 28, 20248-KReg FD Disclosure · Company UpdateMar 22, 20248-KExecutive ChangeMar 14, 202410-KFORM 10-KFeb 23, 2024SC 13GSC 13GFeb 20, 20248-KMaterial Agreement · Company UpdateFeb 12, 20248-KResults of OperationsFeb 6, 20248-KExecutive ChangeFeb 2, 202410-QFORM 10-QNov 7, 20238-KResults of OperationsNov 7, 2023SC 13DSCHEDULE 13DOct 25, 2023SC 13GOCT 2023 FILING, IKENA ONC AS ISSUER FOR GILEAD SCIENCES, THE REPORTING PERSONOct 19, 20238-KMaterial Agreement · New Debt / ObligationSep 14, 2023424B5424B5Sep 11, 2023424B5424B5Sep 7, 20238-KReg FD DisclosureAug 16, 202310-QFORM 10-QAug 4, 20238-KResults of OperationsAug 3, 20238-KExecutive Change · Shareholder VoteMay 5, 202310-QFORM 10-QMay 3, 20238-KResults of OperationsApr 27, 2023DEF 14ADEFINITIVE PROXY STATEMENTMar 23, 2023DEFA14ADEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALSMar 23, 202310-KFORM 10-KFeb 22, 2023SC 13GSEC SCHEDULE 13GFeb 13, 20238-KBylaw AmendmentFeb 6, 2023SC 13GSC 13GFeb 6, 20238-KResults of OperationsFeb 2, 202310-QFORM 10-QNov 2, 20228-KResults of OperationsOct 27, 20228-KReg FD DisclosureSep 12, 202210-QFORM 10-QAug 8, 2022SC 13GSC 13GAug 8, 20228-KResults of OperationsAug 2, 20228-KExecutive ChangeJul 28, 2022
Insider Activity
In the 90 days to Mar 27, 2026: 4 sold $45.4M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 27, 2026 | O'Day Daniel PatrickChairman & CEO | Sell | 10,000 | $136.82 | $1.4M |
| Mar 16, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Sell | 3,000 | $144.23 | $433K |
| Mar 16, 2026 | Dickinson Andrew DChief Financial Officer | Sell | 3,000 | $144.23 | $433K |
| Feb 27, 2026 | O'Day Daniel PatrickChairman & CEO | Sell | 6,419 | $145.18 | $932K |
| Feb 27, 2026 | O'Day Daniel PatrickChairman & CEO | Sell | 3,481 | $144.04 | $501K |
| Feb 27, 2026 | O'Day Daniel PatrickChairman & CEO | Sell | 100 | $145.71 | $15K |
| Feb 17, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Sell | 18,405 | $154.18 | $2.8M |
| Feb 17, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Sell | 9,395 | $154.91 | $1.5M |
| Feb 17, 2026 | Dickinson Andrew DChief Financial Officer | Sell | 3,000 | $154.43 | $463K |
| Feb 17, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Sell | 200 | $155.62 | $31K |
| Feb 5, 2026 | O'Day Daniel PatrickChairman & CEO | Sell | 115,640 | $150.00 | $17.3M |
| Jan 28, 2026 | O'Day Daniel PatrickChairman & CEO | Sell | 5,032 | $139.54 | $702K |
| Jan 28, 2026 | O'Day Daniel PatrickChairman & CEO | Sell | 4,968 | $140.24 | $697K |
| Jan 23, 2026 | O'Day Daniel PatrickChairman & CEO | Sell | 115,640 | $135.00 | $15.6M |
| Jan 20, 2026 | Bluestone JeffreyDirector | Sell | 5,000 | $123.50 | $618K |
| Jan 15, 2026 | Dickinson Andrew DChief Financial Officer | Sell | 3,000 | $124.31 | $373K |
| Jan 15, 2026 | Mercier JohannaChief Commercial Officer | Sell | 3,000 | $124.31 | $373K |
| Dec 29, 2025 | O'Day Daniel PatrickChairman & CEO | Sell | 10,000 | $124.83 | $1.2M |
| Dec 15, 2025 | Mercier JohannaChief Commercial Officer | Sell | 3,000 | $122.00 | $366K |
| Dec 15, 2025 | Dickinson Andrew DChief Financial Officer | Sell | 3,000 | $122.00 | $366K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
🔥 High media attentionCoverage (30d): 8 reputable articles · skews ▼ negative.
MarketWatchGilead Sciences Inc. stock underperforms Friday when compared to competitors despite daily gains3d agoMarketWatchGilead Sciences Inc. stock outperforms competitors despite losses on the day11d agoMarketWatchGilead Sciences Inc. stock underperforms Wednesday when compared to competitors12d agoMarketWatchGilead Sciences Inc. stock outperforms competitors on strong trading day13d agoMarketWatchGilead Sciences Inc. stock underperforms Tuesday when compared to competitors20d ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance